Validation of the newly introduced Deauville score 5a for patients treated for advanced-stage classic Hodgkin lymphoma.
Blood AdvSep 10, 2026
Clinical ResearchOncology (Medical)
Simon Leiders, Dominic Ufton, Helen Kaul et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the prognostic value of the newly defined Deauville score 5a in patients with advanced-stage classical Hodgkin lymphoma (AS-cHL) after two cycles of treatment. The study found that DS5a was associated with inferior progression-free survival (PFS) compared to lower scores, with a hazard ratio of 3.00 (95% CI, 1.25-7.23) in the primary cohort.
Key findings
- DS5a was infrequent, occurring in 4%-6% of patients across cohorts.
- In the primary cohort, DS5 was linked to inferior PFS compared to DS1 to DS3 (HR, 3.00; 95% CI, 1.25-7.23).
- Across sensitivity cohorts, DS5a showed adverse outcomes compared to DS1 to DS4 (HR range, 2.57-5.47).
- Overall survival trends were consistent but limited by few events.
Why it matters
The study highlights the importance of refined prognostic scoring in AS-cHL, which can aid in risk stratification and treatment adaptation based on interim PET results, potentially improving patient outcomes.